CompletedNot applicableNCT03694054

Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers

The Oncology Care Coordination study is designed to evaluate use of a care coordination tool for lung cancer patients and their caregiver on quality of care and performance outcomes. Eligible patients need to be receiving treatment at Geisinger. Participation in the study involves completion of surveys, permission to review information from the patient's electronic health record, and for some enrollment in the care coordination tool called Harmonized Care. Geisinger oncology care providers who have patients enrolled the study will be invited for interviews.

Checked against the public recordLast updated Apr 9, 2019 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorGeisinger Clinic
01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Geisinger Clinic
Interventions being studied
Other: Care coordination tool
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: Patients: * Patients who are 18 years of age or older and diagnosed with lung cancer who 1) are scheduled to start Oncology Care (chemo and/or radiation-therapies) OR 2) on active Oncology Care and recently started within 3 weeks (\<27 days for experimental arm; \<56 days control arm) * Receive care at GMC, GWV, or GCMC * English-speaking * Established/intends to establish a MyGeisinger Account (cases only) Caregivers: * Recognized/intends to be recognized as proxy for patient's MyGeisinger Account (cases only) * English-speaking Providers: \- Any health care provider within Medical Oncology or Radiation Oncology at GMC, where care coordination tool is standard of care, who has a patient enrolled. Exclusion Criteria: Patients: * Patients who are not diagnosed with lung cancer. * Patients who are diagnosed with lung cancer and are on active Oncology Care exceeding 3 weeks (\>27 days experimental arm; \>56 days control arm). Providers: * Any healthcare provider not within the Medical Oncology or Radiation Oncology departments. * Any healthcare provider within Medical Oncology or Radiation Oncology who does not have a patient enrolled (Case Dyad).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Geisinger Health SystemDanville, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 9, 2019. Always confirm current availability with the study team.

View original record ↗